Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RARRES1
REST API REST API
Homo sapiens
RARRES1 is differentially expressed in 263 experiments: 153 organism parts: prostate, trachea, ... (151 more);, 161 disease states: normal, prostate carcinoma, ... (159 more);, 83 cell types 515 cell lines 27 compound treatments and 70 other conditions.
Synonyms TIG1
Orthologs Rarres1 (Mus musculus)   Q0P5D6_BOVIN (Bos taurus)   lxn (Danio rerio)   RARRES1 (Gallus gallus)   Rarres1 (Rattus norvegicus)   rarres1 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term negative regulation of cell proliferation, membrane, integral to membrane
InterPro Term Prot_inh_latexin
UniProt Accession P49788, F8WBG0
Search EB-eye ENSG00000118849
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, E-MTAB-62, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-4717, ... (37 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
MCF-7
1
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
A549
2
E-GEOD-6013, E-GEOD-3202
AGS
2
E-GEOD-15460, E-MTAB-37
BT20
2
E-MTAB-37, E-MTAB-62
DU145
2
E-GEOD-17482, E-GEOD-20089
509 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-21668, E-GEOD-3920, E-MEXP-993, E-MEXP-66, ... (43 experiments)

Factor Value U/D Experiments
monocyte
2
3
E-GEOD-5099, E-GEOD-8286, E-GEOD-995, E-MEXP-2019, E-GEOD-7307 ... (5 experiments)
CD133+ prostate epithelial cell
1
1
E-MEXP-993
PBMCs
1
E-GEOD-20677
spheroid
1
E-GEOD-4219
bronchial epithelial
1
E-MTAB-25
undifferentiated cell
1
E-GEOD-21668
77 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, ... (63 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
3
E-MTAB-62, E-GEOD-96, E-MEXP-2034, E-MEXP-1327
chronic myelogenous leukemia
2
E-GEOD-5550, E-MTAB-62
benign prostatic hyperplasia
2
E-MEXP-2034, E-GEOD-7307
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
cervical carcinoma
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-37, E-MTAB-62
155 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-GEOD-15205, E-GEOD-5824, E-TABM-868, ... (18 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-TABM-868, E-MEXP-1958, E-GEOD-2706
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
unknown
1
E-GEOD-7307
glutamine
1
E-MEXP-941
ethanol
1
E-GEOD-3113
ponasterone A
1
E-GEOD-3113
21 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-2034, ... (10 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-6532, E-MEXP-1901

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-6236, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnicity
studied in E-GEOD-6919

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-20847, E-MEXP-563

Genotype
studied in E-MEXP-1996, E-GEOD-1923, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-MEXP-2657, E-GEOD-12773, E-GEOD-20504, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-TABM-26, E-TABM-15, ... (34 experiments)

Infection
studied in E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-3407

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1315

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-19246, E-GEOD-13818, E-GEOD-15799

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-1561, E-GEOD-6532, E-GEOD-4922, ... (6 experiments)

Processing time: 0.586 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM